Online inquiry

IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13387MR)

This product GTTS-WQ13387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8594MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ10953MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ4355MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ3041MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14105MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ11541MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ11618MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW